万泰生物：全资子公司入围国家免疫规划疫苗集中采购项目

Core Viewpoint - Company WanTai BioPharma (603392.SH) has successfully entered the bidding for the 2025 National Immunization Program vaccine procurement project for the bivalent human papillomavirus (HPV) vaccine, with a unit price of RMB 27.5 [1][2] Group 1 - The bivalent HPV vaccine (E. coli) is designed to prevent diseases caused by high-risk HPV types 16 and 18, including cervical cancer and various cervical intraepithelial neoplasia (CIN) [1] - The company has responded to the World Health Organization's initiative to eliminate cervical cancer globally, with global sales of the product reaching approximately 80 million doses as of the announcement date [1] - The inclusion of the product in the procurement project is expected to enhance the HPV vaccination rate in China, contributing to the country's goal of eliminating cervical cancer [1] Group 2 - The centralized procurement is organized by the Chinese Center for Disease Control and Prevention, and if the company signs procurement contracts and organizes production and supply, it will help expand the sales scale of the included products [2] - This will improve the market share of the company's included products and promote the development of the domestic market, thereby enhancing the company's brand influence [2]